• TKI Treatment Sequencing in Advanced Gastrointestinal Stromal TumorsDownload PDF   PMID: 36607590 
  • ​Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial   Download PDF   PMID: 36514034
  • ​Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.   Download PDF   PMID: 35947817
  • Ten-Year Survivorship in Patients with Metastatic Gastrointestinal Stromal Tumors.  Download PDF  PMID: 35829795
  • A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor,  Download PDF   PMID 35524239
  • Neoadjuvant tyrosine kinase inhibitor therapy for patients with gastrointestinal stromal tumor: A propensity-matched analysis.  Download PDF   PMID 35382931
  • New treatment strategies for advanced-stage gastrointestinal stromal tumours. Download PDF   PMID 35217782
  • Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers.  Download PDF   PMID 35091442
  • Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response.  Download PDF  PMID 34426440


  • Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.  Download PDF   PMID 34391056
  • Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.  ​Download PDF  PMID 34343033
  • Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity.  Download PDF  PMID 34326133
  • ​Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor.  Download PDF  PMID 34322383
  • Hepatic metastases in gastrointestinal stromal tumors: oncologic outcomes with curative-intent hepatectomy, resection of treatment-resistant disease, and tyrosine kinase inhibitor therapy alone.  Download PDF   PMID 34924291
  • Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study.  Download PDF   PMID 34503977
  • ​Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.  Download PDF  PMID 34313371
  • ​Imatinib-resistant gastrointestinal stromal tumors in the era of second- and third-line tyrosine kinase inhibitors: Does surgical resection have a role?  Download PDF  PMID 34090672
  • ASO Author Reflections: The Disease-Free Interval is Associated with Oncologic Outcomes for Patients with Recurrent Gastrointestinal Stromal Tumor. Download PDF  PMID 33987756
  • ​​Inhibition of KIT Tyrosine Kinase Activity: Two Decades After the First Approval.  Download PDF  PMID 33797935
  • ​Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data.  Download PDF  PMID 33740926
  • ​​Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis.  Download PDF  PMID 33603171
  • ​​Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.  Download PDF  PMID 33465704
  • Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least 3 Prior Lines of Therapy.  Download PDF  PMID: 33453089


  • Identification of Wee1 as target in combination with avapritinib for Gastrointestinal Stromal Tumor treatment.  Download PDF  PMID: 33320833 
  • Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.  Download PDF  PMID: 32804590
  • Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain.  Download PDF  PMID: 32972961
  • Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.  Download PDF  PMID: 32511981
  • Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.  Download PDF  PMID: 32615108 
  • Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study.  Download PDF  PMID: 31792037


  • Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.  Download PDF PMID: 31755321
  • KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy. Download PDF PMID: 31308077
  • Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group RegistryDownload PDF  PMID: 30984366
  • Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs).  Download PDF   PMID: 30867899
  • ​​Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.  Download PDF   PMID: 31085175
  • Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Download PDF   PMID: 30792533
  • LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma.  Download PDF   PMID: 30242244


  • Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases.   Download PDF    PMID: 2996412
  • ​Translational insights into gastrointestinal stromal tumor and current clinical advances. Download PDF  PMID: 30101284
  • Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene.  Download PDF   PMID: 2951053​0


  • A precision therapy against cancers driven by KIT/PDGFRA mutations.  Download PDF   ​PMID: 29093181
  • Defining the Impact of Adjuvant Therapy in Molecularly Defined Subsets of Gastrointestinal Stromal Tumor : From Lumping to Splitting. Download PDF  PMID: 28334361
  • ​Gastrointestinal stromal tumours of the oesophagus: a clinicopathological and molecular analysis of 27 cases.  Download PDF
  • Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown Significance.  Download PDF   PMID: 28724664
  • Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors.  Download PDF   PMID: 28317407
  • ​​MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation.  Download PDF​   ​PMID: 28270683
  • Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.  PMID: 28196207
  • PDGFRA Antibody for Soft Tissue Sarcoma.  Download PDF  PMID: 28187274


  • ​​FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.  Download PDF  PMID: 27974047
  • Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib.  PMID: 27167336
  • ​Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.   Download PDF​  PMID: 27156227
  • Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.  Download PDF   PMID: 26772734


  • S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors.  Download PDF   PMID: 26576593
  • Utility of BRAF V600E mutation-specific immunohistochemistry in detecting BRAF V600E-mutated gastrointestinal stromal tumors.  Download PDF  PMID: 26486743
  • SDHC methylation in gastrointestinal stromal tumors (GIST): a case report.  Download PDF  PMID: 26415883
  • Genotyping and immunohistochemistry of gastrointestinal stromal tumors: An update.  PMID: 25766843 
  • Template for Reporting Results of Biomarker Testing of Specimens From Patients With Gastrointestinal Stromal Tumors.  Download PDF PMID: 25729899
  • Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.  Download PDF  PMID: 25695690  
  • Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance.  Download PDF  PMID: 25432174  
  • Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways.  Download PDF  PMID: 25165019  


  • Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST).           Download PDF  PMID: 25239601
  • Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.  Download PDF  PMID: 25239608
  • Combination therapy for KIT-mutant mast cells: Targeting constitutive NFAT and KIT activity.  Download PDF            PMID: 25253785
  • Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract.  Download PDF            PMID: 24842760
  • Regorafenib for treatment of advanced gastrointestinal stromal tumors. Download PDF  PMID: 24405315
  • KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation. PMID: 24687822
  • Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.  PMID: 24638003
  • Novel Mutations in Neuroendocrine Carcinoma of the Breast: Possible Therapeutic Targets.  Download PDF           PMID: 24569783
  • Gastrointestinal stromal tumors: what do we know now?  Download PDF  PMID: 24384849



  • Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. Download PDF  PMID: 23775962
  • Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. Download PDF  PMID: 23705826
  • Gastrointestinal stromal tumour.Download PDF  PMID: 23623056
  • Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. Download PDF  PMID: 23497317
  • Combining Highly Multiplexed PCR with Semiconductor-Based Sequencing for Rapid Cancer Genotyping.     PMID: 23274167
  • BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Download PDF  
  • Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors.Download PDF  PMID: 23313954


  • Multiplex mutation screening by mass spectrometry in gastrointestinal stromal tumours.  PMID: 22777070
  • Regorafenib Induces Rapid and Reversible Changes in Plasma Nitric Oxide and Endothelin-1.  Download PDF  PMID: 22785409
  • Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-resistant Gastrointestinal Stromal Tumors.  Download PDF  PMID: 22745105
  • Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.   Download PDF  PMID: 22705004
  • Sorafenib Inhibits Many Kinase Mutations Associated with Drug-Resistant Gastrointestinal Stromal Tumors.  Download PDF  PMID: 22665524
  • Multiplex high-throughput gene mutation analysis in acute myeloid leukemia.  Download PDF  PMID: 22658276
  • Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial.  Download PDF  PMID: 22614970
  • Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.  Download PDF  PMID: 22203182   Erratum to "Phase II..."  
  • Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study.  Download PDF  PMID: 22804613


  • Differential expression of neural markers in KIT and PDGFRA wild-type gastrointestinal stromal tumors.  Download PDF  PMID: 22175887
  • Gastrointestinal stromal tumours: origin and molecular oncology.   Download PDF  PMID: 22089421
  • A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients.  Download PDF  PMID: 21994214
  • Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Download PDF  PMID: 21953054
  • Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. Download PDF  PMID: 21726664
  • ​"Pediatric-type" Gastrointestinal Stromal Tumors in Adults: Distinctive Histology Predicts Genotype and Clinical Behavior.  Download PDF  PMID: 21358303